





Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms with Prophylactic Pentosan Polysulphate in Patients with Non-Muscle-Invasive Bladder Cancer: A **Randomized Controlled Trial**

INTRODUCTION

- Bacillus Calmette-Guerin (BCG) remains the most effective prophylactic treatment of intermediate and high-risk nonmuscle invasive bladder cancer.
- 30 to 60% of bladder cancer patients experienced systemic and local adverse events of variable severity following intravesical BCG therapy
- Only 16 to 29% of patients completed all the three-year BCG treatment regimen.
- Guidelines recommend medications, such as oxybutynin phenazopyridine, and propantheline bromide for short term symptomatic relief.
- Pentosan Polysulphate (PPS) is an oral medication with unique analgesic properties used to relieve bladder pain and discomfort related to conditions of bladder inflammation (Interstitial Cystitis / Bladder pain syndrome).
- Pentosan Polysulphate acts by replacing the mucus in the glycosaminoglycan layer of damaged urothelium in the bladder.

OBJECTIVES

Hypothesis:

Concomitant administration of oral PPS and intravesical BCG can prevent and decrease BCG-related LUTS.

Primary Objective:

1. Determine the efficacy and safety of co-administration of Pentosan Polysulphate (100mg) versus placebo administered orally thrice daily for 6 weeks in preventing BCG-related LUTS in adult subjects with a diagnosis of NMIBC.

2. Assess the impact of this intervention on Health-related quality of life in bladder cancer patients.

Secondary Objectives:

. Evaluate the efficacy of BCG therapy following coadministration of PPS in patients with a diagnosis of NMIBC.

2. Identify the predisposing factors to developing BCG-related LUTS based on clinical, demographic and voiding parameters.



Samer Shamout, Simon Tanguay, Maurice Anidjar, Lysanne Campeau CQI Research Grant 2017


METHODS / INTERVENTIONS Study Design • Phase 2, double-blind, randomized, placebo-controlled, parallel-group study • Multicentre trial involving two partner sites: (Jewish General Hospital, McGill University Health Centre) Outcomes **Primary outcomes (change from baseline to end of treatment):** Mean change in number of urgency episodes/24hr (3-day bladder diary) Mean change in ICIQ-LUTSqol score Mean change in OAB-V8 score Secondary outcomes (change from baseline to end of treatment): Mean change in VAS score Mean change in urinary inflammatory markers (TRAIL, IFN, IL-2, IL-10) Cystoscopy and urine Cytology at 3 and 6 months **STUDY FLOW DIAGRAM** Assessment for eligibility (n=120) Exclusion criteria nclusion criteria Adult patients 18 to 85 years old Willing to provide written consent Tumor stage \geq T2, CIS Confirmed diagnosis (biopsy-proven) of intermediate- and high-risk NMIBC 2-4 weeks following tumor resection Candidate for BCG induction therapy No-intervention grou n=40` At week0, (Prior to BCG Pentosan Polysulphate induction treatment) 100mg orally TID for Clinical, demographic 6 weeks & voiding parameters (n=30) Questionnaires (OAB-V8, ICIQ-LUTSqol, VAS) At week 0 and 6 (End of treatment) Urinary inflammatory • Urgency Episodes/24hr (3-day bladder diary) markers (TRAIL, IFN, • Questionnaires (OAB-V8, ICIQ-LUTSqol, VAS) IL-2, IL-10) O At week 6, (End of BCG At screening, week 0,6, and 26 (End of study) Physical examination induction treatment) Clinical, demographic & • Urine analysis and culture voiding parameters • Post-void residual (PVR) Questionnaires (OAB-• Cystoscopy & urine cytology V8, ICIQ-LUTSqol, VAS) • Coagulation profile and Liver function tests Urinary inflammatory • Recording of Adverse Events Follo markers (TRAIL, IFN, IL-

2, IL-10)



Centre universitaire de santé McGill Health Centre





PATIENT IMPACT

- Improve patient experience by identifying predictor markers rendering patients at higher risk of developing BCG-related LUTS.
- This will guide patient counselling before treatment to inform them about associated risks and benefits of the BCG treatment.
- We will determine the role of prophylactic PPS to prevent these LUTS from occurring, particularly if patients are considered at higher risk, and therefore improve patient experience.
- The improvement measurements are validated in the assessment of lower urinary tract symptoms related to BCG therapy (voiding diary and OAB-V8) and their quality of life (ICIQ-LUTSqol).

REFERENCES

- 1. Advisory CCSs, Statistics CoC. Canadian cancer statistics. October 2016 ed. Toronto, ON:Canadian Cancer Society; 2016.
- 2. Kassouf W, Traboulsi SL, Kulkarni GS, et al. CUA guidelines on the management of nonmuscle invasive bladder cancer. Can Urol Assoc J. 2015;9(9-10):E690-704.
- 3. Yadav S, Tomar V, Yadav SS, Priyadarshi S, Banerjee I. Role of oral pentosane polysulphate in the reduction of local side effects of BCG therapy in patients with nonmuscle-invasive bladder cancer: a pilot study. BJU international. 2016;118(5):758-762.
- 4. Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. The Journal of urology. 2011;186(6):2158-2167.

TRANSLATION ACROSS THE RCN

- The proposed study will provide evidence to guide larger scale studies that may change our practice. Evidence-based treatment intervention (Pentosan Polysulphate) will help to improve bladder cancer patients' quality of life and optimize the effectiveness of BCG treatment.
- This can effectively reduce patient hospital stay and outpatient visits and hence, treatment related cost. Moreover, it will minimize the burden of bladder cancer-treatment-related adverse events in Quebec.
- The proposed study is completely aligned with the MSSS and Direction generale de cancerologie, as it will continue to give highest quality care to NMIBC patients with BCG treatment, as it currently is recommending.
- The study will identify predictive marker to improve informed consent and direct prophylactic measure to avoid complications such as BCG related LUTS.

